{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:20:03Z","timestamp":1786994403923,"version":"build-2736575974"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008746","name":"National Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008746","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Magnetic Resonance Imaging"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.mri.2025.110534","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T04:44:07Z","timestamp":1760071447000},"page":"110534","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Combination of clinicopathological and MRI based radiomics features in predicting homologous recombination repair genes mutations in prostate cancer"],"prefix":"10.1016","volume":"124","author":[{"given":"Ruchuan","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqing","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingni","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hualei","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangping","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajia","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.mri.2025.110534_bb0005","first-page":"209","article-title":"Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.mri.2025.110534_bb0010","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"10.1016\/j.mri.2025.110534_bb0015","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","article-title":"Prostate Cancer, version 4.2023, NCCN clinical practice guidelines in oncology","volume":"21","author":"Schaeffer","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"10.1016\/j.mri.2025.110534_bb0020","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","article-title":"Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study","volume":"16","author":"Ryan","year":"2015","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.mri.2025.110534_bb0025","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1016\/S1470-2045(19)30688-6","article-title":"Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial","volume":"20","author":"Khalaf","year":"2019","journal-title":"Lancet Oncol"},{"issue":"10398","key":"10.1016\/j.mri.2025.110534_bb0030","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","article-title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Agarwal","year":"2023","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.mri.2025.110534_bb0035","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1200\/JCO.22.01649","article-title":"Niraparib and abiraterone acetate for metastatic castration-resistant prostate Cancer","volume":"41","author":"Chi","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.mri.2025.110534_bb0040","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/s41467-023-35880-y","article-title":"CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer","volume":"14","author":"Tsujino","year":"2023","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.mri.2025.110534_bb0045","doi-asserted-by":"crossref","first-page":"559","DOI":"10.2214\/AJR.15.14967","article-title":"Quantitative multiparametric MRI features and PTEN expression of peripheral zone prostate Cancer: a pilot study","volume":"206","author":"McCann","year":"2016","journal-title":"AJR Am J Roentgenol"},{"issue":"3","key":"10.1016\/j.mri.2025.110534_bb0050","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1002\/jmri.29186","article-title":"Association of Pathological Features and Multiparametric MRI-based radiomics with TP53-mutated prostate Cancer","volume":"60","author":"Chen","year":"2024","journal-title":"J Magn Reson Imaging"},{"issue":"11","key":"10.1016\/j.mri.2025.110534_bb0055","doi-asserted-by":"crossref","first-page":"7165","DOI":"10.1245\/s10434-022-11958-7","article-title":"A multiomics signature highlights alterations underlying homologous recombination deficiency in triple-negative breast Cancer","volume":"29","author":"Su","year":"2022","journal-title":"Ann Surg Oncol"},{"issue":"30","key":"10.1016\/j.mri.2025.110534_bb0060","doi-asserted-by":"crossref","first-page":"3550","DOI":"10.1200\/JCO.23.02641","article-title":"Deep learning artificial intelligence predicts homologous recombination deficiency and platinum response from histologic slides","volume":"42","author":"Bergstrom","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.mri.2025.110534_bb0065","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.eururo.2017.01.033","article-title":"Improving the Rotterdam European randomized study of screening for prostate Cancer risk calculator for initial prostate biopsy by incorporating the 2014 International Society of Urological Pathology Gleason Grading and Cribriform growth","volume":"72","author":"Roobol","year":"2017","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.mri.2025.110534_bb0070","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/pcan.2010.16","article-title":"Histological characteristics of the index lesion in whole-mount radical prostatectomy specimens: implications for focal therapy","volume":"14","author":"Karavitakis","year":"2011","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.mri.2025.110534_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejrad.2023.110763","article-title":"Index lesion contouring on prostate MRI for targeted MRI\/US fusion biopsy - evaluation of mismatch between radiologists and urologists","volume":"162","author":"Ghafoor","year":"2023","journal-title":"Eur J Radiol"},{"issue":"2","key":"10.1016\/j.mri.2025.110534_bb0080","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.acra.2018.01.023","article-title":"Breast Cancer molecular subtype prediction by mammographic radiomic features","volume":"26","author":"Ma","year":"2019","journal-title":"Acad Radiol"},{"key":"10.1016\/j.mri.2025.110534_bb0085","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.700782","article-title":"Immune-based prediction of COVID-19 severity and chronicity decoded using machine learning","volume":"12","author":"Patterson","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.mri.2025.110534_bb0090","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1305543","article-title":"Synthetic minority over-sampling technique-enhanced machine learning models for predicting recurrence of postoperative chronic subdural hematoma","volume":"15","author":"Ni","year":"2024","journal-title":"Front Neurol"},{"issue":"3","key":"10.1016\/j.mri.2025.110534_bb0095","doi-asserted-by":"crossref","DOI":"10.3390\/cells10030659","article-title":"Signaling pathways in Cancer: therapeutic targets, combinatorial treatments, and new developments","volume":"10","author":"Yip","year":"2021","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.mri.2025.110534_bb0100","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.cell.2018.03.035","article-title":"Oncogenic Signaling pathways in the Cancer genome atlas","volume":"173","author":"Sanchez-Vega","year":"2018","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.mri.2025.110534_bb0105","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12859-020-3423-z","article-title":"Comparison of pathway and gene-level models for cancer prognosis prediction","volume":"21","author":"Zheng","year":"2020","journal-title":"BMC Bioinform"},{"issue":"4","key":"10.1016\/j.mri.2025.110534_bb0110","article-title":"Pan-cancer analysis of pathway-based gene expression pattern at the individual level reveals biomarkers of clinical prognosis","volume":"1","author":"Su","year":"2021","journal-title":"Cell Rep Methods"},{"issue":"18","key":"10.1016\/j.mri.2025.110534_bb0115","article-title":"Integration analysis of single-cell multi-omics reveals prostate Cancer heterogeneity","volume":"11","author":"Bian","year":"2024","journal-title":"Adv Sci (Weinh)"},{"issue":"5","key":"10.1016\/j.mri.2025.110534_bb0120","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.urolonc.2024.01.037","article-title":"Ductal, intraductal, and cribriform carcinoma of the prostate: molecular characteristics and clinical management","volume":"42","author":"Shi","year":"2024","journal-title":"Urol Oncol"},{"key":"10.1016\/j.mri.2025.110534_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2021.153507","article-title":"Homologous recombination repair gene mutations in Chinese localized and locally advanced prostate cancer patients","volume":"224","author":"Jiang","year":"2021","journal-title":"Pathol Res Pract"},{"issue":"5","key":"10.1016\/j.mri.2025.110534_bb0130","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/j.1467-9868.2011.00783.x","article-title":"Penalized classification using fisher\u2019s linear discriminant","volume":"73","author":"Witten","year":"2011","journal-title":"J R Stat Soc Series B Stat Methodol"},{"issue":"12","key":"10.1016\/j.mri.2025.110534_bb0135","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/nrclinonc.2017.141","article-title":"Radiomics: the bridge between medical imaging and personalized medicine","volume":"14","author":"Lambin","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"10.1016\/j.mri.2025.110534_bb0140","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.humpath.2010.02.011","article-title":"Multifocal prostate cancer: biologic, prognostic, and therapeutic implications","volume":"41","author":"Andreoiu","year":"2010","journal-title":"Hum Pathol"},{"issue":"3","key":"10.1016\/j.mri.2025.110534_bb0145","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.eururo.2018.08.009","article-title":"Multifocal primary prostate Cancer exhibits high degree of genomic heterogeneity","volume":"75","author":"Lovf","year":"2019","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.mri.2025.110534_bb0150","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41585-020-00400-w","article-title":"Genomic and phenotypic heterogeneity in prostate cancer","volume":"18","author":"Haffner","year":"2021","journal-title":"Nat Rev Urol"},{"issue":"10","key":"10.1016\/j.mri.2025.110534_bb0155","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1002\/1878-0261.13511","article-title":"Prospective clinical sequencing of 1016 Chinese prostate cancer patients: uncovering genomic characterization and race disparity","volume":"17","author":"Wei","year":"2023","journal-title":"Mol Oncol"},{"issue":"1","key":"10.1016\/j.mri.2025.110534_bb0160","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41556-020-00613-6","article-title":"Single-cell analysis reveals transcriptomic remodellings in distinct cell types that contribute to human prostate cancer progression","volume":"23","author":"Chen","year":"2021","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.mri.2025.110534_bb0165","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.906370","article-title":"Neoadjuvant Chemohormonal therapy in prostate Cancer before radical prostatectomy: a systematic review and Meta-analysis","volume":"12","author":"Ge","year":"2022","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.mri.2025.110534_bb0170","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1200\/JCO.2017.74.1173","article-title":"Role of genetic testing for inherited prostate Cancer risk: Philadelphia prostate Cancer consensus conference 2017","volume":"36","author":"Giri","year":"2018","journal-title":"J Clin Oncol"},{"issue":"7639","key":"10.1016\/j.mri.2025.110534_bb0175","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nature21056","article-title":"Dermatologist-level classification of skin cancer with deep neural networks","volume":"542","author":"Esteva","year":"2017","journal-title":"Nature"}],"container-title":["Magnetic Resonance Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0730725X25002188?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0730725X25002188?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T02:13:02Z","timestamp":1762308782000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0730725X25002188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":35,"alternative-id":["S0730725X25002188"],"URL":"https:\/\/doi.org\/10.1016\/j.mri.2025.110534","relation":{},"ISSN":["0730-725X"],"issn-type":[{"value":"0730-725X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination of clinicopathological and MRI based radiomics features in predicting homologous recombination repair genes mutations in prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Magnetic Resonance Imaging","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mri.2025.110534","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110534"}}